Proceeds from the financing will support the acceleration of ITI's Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, and expand upon the current applications of its UNITE platform. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Recruiters: We do not accept unsolicited resumes from any source other than directly from the candidate. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. To explore Immunic Therapeutics's full profile, request access. 301-968-3501 amy@juniper-point.com Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . You will receive a reply to confirm the receipt of your application. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. Company Type For Profit. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. mcarey@rxir.com This represents the second closing in the investment process for the HLB Consortium, ($10M was placed in February 2020), and substantially increases their holding in Immunomic Therapeutics to 47.6% of the common stock. We are also collaborating with academic centers and biotechnology companies to study the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI maintains its headquarters in Rockville, Maryland. 2017 Apr 15;23(8):1898-1909. Immunomic, Colmmune partner on cancer immunotherapy By The Science Advisory Board staff writers. In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. Immunomic Therapeutics is a biotech company committed to patients. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. News Releases | PharmaJet UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. Founders Sungwuk Kim. The Company has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke. Director of Research and Development at Immunomic Therapeutics, Inc. - most recent Rockville, Maryland, United States. Phone Number +119196161923. William Hearl - President & CEO - Immunomic Therapeutics, Inc See Immunomic Therapeutics funding rounds, investors, investments, exits and more. Checkmate-548 was the most recent hope for Opdivo in glioblastoma following the failures, in 2017 and 2019 respectively, of Checkmate-143 in the second-line setting and Checkmate-498 in first-line. Coordinates: 245831.9N 1213154.0E. Immunomic Therapeutics, Inc. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleic acid-based immunotherapy today announced the appointment of Brian Stamper to Vice President, Cell Therapy Operations. Immunomic Therapeutics investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies. J Immunol Res. SaaS, Android, Cloud Computing, Medical Device). Bard (Becton, Dickinson and Company). The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . 301-968-3501, ITI Media: ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics. The New Taipei Municipal Hsin Tien Senior High School ( Chinese: ) is a senior high school in Xindian District, New Taipei, Taiwan which was founded in 1992. Ms. Harrison brings to the company more than 30 years of experience in global regulatory strategies and submissions, interactions, intelligence and advocacy. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Prior to that, Mr. Stamper held positions of increasing responsibility in various operational areas at Lonza Pharmaceuticals and Biotechnology, AstraZeneca Biologics and Eli Lilly & Company. Company profile for HLB Co. Ltd. including key executives, insider trading, ownership, revenue and average growth rates. Immunomic Therapeutics - Products, Competitors, Financials, Employees 15010 Broschart Dr., Suite 110, Rockville, MD 20850. Description. ITI-ID Candidate Multiple infectious diseases. Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . Immunic Therapeutics Company Profile: Stock Performance & Earnings ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. 15010 Broschart Road Suite 250. For more information, please visit www.immunomix.com. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. Our goal is to overcome the limitations of current immuno-oncology therapies by . Book the hotel with real traveler reviews, ratings and latest pictures of Chinatrust Executive House Hsin-Tien. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). The foundation of a successful company is only as strong as the quality of its employee team. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. Immunomic Therapeutics Company Profile: Valuation & Investors | PitchBook activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. Sia Anagnostou Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Melissa Kemp ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. Chinatrust Executive House Hsin-Tien-New Taipei City Updated 2022 Room Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. The company was founded in 2005 and is based in Lancaster, Pennsylvania. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. The company is developing three small molecule products; its lead development program, IMU-838, a selective . While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific). Very family oriented. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Arruda L.B., et al., Dendritic Cell-Lysosomal-Associated Membrane Protein (LAMP) and LAMP-1-HIV-1 Gag Chimeras Have Distinct Cellular Trafficking Pathways and Prime T and B Cell Responses to a Diverse Repertoire of Epitopes. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Immunomic Therapeutics Announces First Patient Dosed in Phase I If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics may be just for you. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. Immunomic Therapeutics (ITI) is a clinical stage biotechnology company pioneering investigational technologies that have the potential to alter how immunotherapy is used for cancer, allergies, and animal health. With HLBs support, we are well-positioned to accelerate our efforts in immuno-oncology, in particular glioblastoma multiforme, and rapidly advance other key candidates in our pipeline, including our most recent initiative into infectious diseases with development of our vaccine candidate for COVID-19.. The initial foray into immuno-oncology was undertaken when ITI decided to support the work of Drs. Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information IMU-935, a selective inverse agonist of the transcription factor RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome. Founded Date 2015. Batich, K.A., Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. ITIs UNITE platform combines its core lysosomal targeting technology with novel formulation, delivery, and adjuvant complements. Melody Carey Senior Scientist/Scientist II, Formulation Development. CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. Teri Heiland - Chief Scientific Officer (CSO) - Immunomic Therapeutics San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Careers - Immunomic Therapeutics Internally, we are able to supply the R&D Team with UNITE products in a timely manner for their ongoing oncology studies. Working at Immunomic Therapeutics | Glassdoor These factors are currently under intense focus in the cancer immunotherapy landscape. Glioblastoma Multiforme (GBM) - Immunomic Therapeutics Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. 2015 Mar 19;519(7543):366-9. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Find all information and best deals of Chinatrust Executive House Hsin-Tien, New Taipei City on Trip.com! We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. We provide a professional and challenging work environment . Rockville's Immunomic Therapeutics Inc. is on track to go public later this year, after Covid-19 threw a wrench in the vaccine maker's initial timeline. Jan 2006 - Present17 years 2 months. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Amy Conrad pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. We know that there are multiple aspects that inform our platform's success. While research is the essential engine that drives our technology forward, our efforts in process development, manufacturing management, and regulatory affairs are critical factors that advance the Immunomic Therapeutics vision. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Evaluate their financials based on Immunomic Therapeutics's post-money valuation and revenue. Join to follow . Immunomic Therapeutics Announces the Appointment of Frances Harrison as We are pleased to welcome HLB as a significant shareholder of Immunomic Therapeutics and look forward to working with them within the framework of the HLB Bio family of companies. Mohan Karkada - Director of Research and Development - LinkedIn ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. In addition to our pipeline, we are also developing through collaborations with academic centers and biotechnology companies the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. It is important to note that, while the mechanism of lysosomal targeting appears to focus on enhancing presentation of antigen to CD4+ T cells and producing a Th1 type CD4+ T cell response (an aspect missing in other platforms), the UNITE platform, as a whole, is believed to induce a broad immune response and can result in enhanced CD8+ T cell responses as well. For more information, please visit www.immunomix.com. Companies - Johns Hopkins Technology Ventures What is health insurance like at Immunomic Therapeutics. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in this tumor type and others. Due to the volume of inquiries received, we regret that we cannot contact all applicants personally. Immunomic Therapeutics Announces License Agreement With Lineage Cell CONTACT US. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Immunic Therapeutics Investments & Acquisitions (2) Company Name Deal Date Deal Type Deal Size Industry Lead Partner; 00000 0000000: 12-Apr-2019: 0000000000: Drug Discovery: 000000 00: 4SC (immunology portfolio) 28-Sep-2016: Immunomic Therapeutics, Inc. | LinkedIn A $300 million worldwide licensing agreement announced last week between Immunomic Therapeutics and Astellas Pharma to develop treatment for a wide range of allergic diseases, including peanut allergies, is the largest deal ever to come out of Johns Hopkins Technology Ventures, the patent, licensing, and technology . Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. ITI-1001 GBM - pDNA. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. aanagnostou@immunomix.com Pay, Holidays and PTO appear to be very good. New Taipei Municipal Hsin Tien Senior High School - Wikipedia UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus.
Luke Thenotable 2000 Days Seed,
Women's Figure Skating Olympics 2022 Final Results,
Arizona High School Wrestling State Champions Archive Individual,
Articles I
immunomic therapeutics crunchbase